JP Morgan
TD Cowen, JP Morgan Initiate Coverage of Tempus AI With Buy, Overweight Ratings
Cowen said that Tempus is a differentiated oncology diagnostics company with an order backlog from pharma clients and the potential for strong growth and rising margins.
Illumina Enters Into $750M Credit Agreement With JP Morgan to Fund Grail Divestment
Illumina said the proceeds may be used "to fund cash to the balance sheet of Grail, in connection with [Illumina's] planned divestment of Grail."
JP Morgan Downgrades Pacific Biosciences to Neutral
The downgrade follows the sequencing instrument maker's announcement last week of a revenue shortfall for Q1 along with lowered revenue guidance for 2024.
JP Morgan Healthcare Conference, Day 3: PacBio, Grail, Seer, Akoya, Myriad, More
Highlights from the third day included PacBio's plans for a high-throughput long-read sequencer, Akoya's 2.0 platforms, and Myriad's goals for its MRD test.
NanoString Technologies Banking on Spatial Biology Growth Despite Tumultuous 2023
At the JP Morgan Healthcare Conference, CEO Brad Gray said the company expects to capture spatial biology market share even after a string of legal losses and layoffs.